The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis

Diabetes and Metabolism

Volumn 34, Issue 6 PART 2, 2008, Pages 685-691

  Cariou, B ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Bile acids; FXR; Lipogenesis; Liver regeneration; Liver steatosis; Review

Indexed keywords

BILE ACID; CELL RECEPTOR; DNA BINDING PROTEIN; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; INSULIN; ISOXAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL; ARTICLE; CHROMOSOME 12; CHROMOSOME MAP; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; FATTY LIVER; GENETICS; HUMAN; LIVER REGENERATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 12; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FATTY LIVER; HUMANS; INSULIN; ISOXAZOLES; LIVER REGENERATION; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 62749205848     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(08)74605-6     Document Type: Article

References (56)

1. Cariou B, Staels B. FXR:a promising target for the metabolic syndrome? Trends Pharmacol Sci 2007;28:236-43.
2. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006;31:572-80.
3. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003;278:104-10.
4. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995;81:687-93.
5. Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 1995;9:72-85.
6. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-5.
7. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-8.
8. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-53.
9. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000;43:2971-4.
10. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005;25:2020-30.
11. Stellaard F, Sackmann M, Sauerbruch T, Paumgartner G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res 1984;25:1313-9.
12. Kuipers F, Claudel T, Sturm E, Staels B. The Farnesoid X Receptor [FXR] as modulator of bile acid metabolism. Rev Endocr Metab Disord 2004;5:319-26.
13. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bil e acid homeostasis. Cell Metab 2005;2: 217-25.
14. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004;53:890-8.
15. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005;280:29971-9.
16. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha [PGC- 1alpha] regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 2004;18:157-69.
17. Cariou B, van HK, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281: 11039-49.
18. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-9.
19. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103:1006-11.
20. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002;1585:202-12.
21. Rizzo G, Disante M, Mencarelli A, Renga B, Gioiello A, Pellicciari R, et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 2006;70:1164-73.
22. Shen H, Zhang Y, Ding H, Wang X, Chen L, Jiang H, et al. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem 2008;22:1-14.
23. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484-9.
24. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006;313:1137-40.
25. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113: 1408-18.
26. Gibbons GF. Assembly and secretion of hepatic very-low-density lipoprotein. Biochem J 1990;268:1-13.
27. Pineda T, I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259-72.
28. Savkur RS, Bramlett KS, Michael LF, Burris TP. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem Biophys Res Commun 2005;329:391-6.
29. Day CP, James OF. Steatohepatitis:a tale of two "hits"? Gastroenterology 1998;114:842-5.
30. Kong B, Luyendyk JP, Tawfik O, Guo GL. FXR-deficiency Induces Non-alcoholic Steatohepatitis in LDLr-knockout Mice Fed a Highfat Diet. J Pharmacol Exp Ther 2008 Oct 23 [Epub ahead of print].
31. Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol 2004;67:1389-97.
32. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J Biol Chem 2003;278:8988-95.
33. Qin P, Borges-Marcucci LA, Evans MJ, Harnish DC. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes. Am J Physiol Gastrointest Liver Physiol 2005;289:G267-G273.
34. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 2005;314:584-95.
35. Lee FY, Kast-Woelbern HR, Chang J, Luo G, Jones SA, Fishbein MC, et al. Alpha-crystallin is a target gene of the farnesoid X-activated receptor in human livers. J Biol Chem 2005;280:31792-800.
36. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008;48:1632-43.
37. Safadi R, Friedman SL. Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed 2002;4:27.
38. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004;127:1497-512.
39. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, et al. Cross-talk between farnesoid-X-receptor [FXR] and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005;315:58-68.
40. Jung D, Mangelsdorf DJ, Meyer UA. Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem 2006;281:19081-91.
41. Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM, et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci USA 2006;103:11323-8.
42. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003;125:825-38.
43. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003;112: 1678-87.
44. Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, et al. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003;124:1926-40.
45. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006;290:G1124-G1130.
46. Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res 2008;in press.
47. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006;312:233-6.
48. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007;28:940-6.
49. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007;67:863-7.
50. Wang YD, Yang F, Chen WD, Huang X, Lai L, Forman BM, et al. Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. Mol Endocrinol 2008;22:1622-32.
51. Wittenburg H, Lyons MA, Li R, Churchill GA, Carey MC, Paigen B. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology 2003;125:868-81.
52. Chetiveaux M, Zair Y, Disse E, Pouteau E, Costet P, Laville M, et al. Association of plasma bile acids concentrations with insulin sensitivity in humans. Diabetes 2008;57:A-3273 [Abstract].
53. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007;67:1383-92.
54. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-22.
55. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study [GLOWS]: a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83.
56. Evans MJ, Mahaney PE, Zhang S, Gantan E, Borges-Marcucci LA, Lai K, et al. A synthetic farnesoid X receptor agonist protects against diet-induced dyslipidemia. Circulation 2007;117:584 [Abstract].